Resmetirom: An Orally Administered, Small-molecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
Gres Karim, Meena B Bansal
Non–alcoholic fatty liver disease (NAFLD) encompasses a spectrum of fatty liver diseases, including non–alcoholic fatty liver (NAFL) and non–alcoholic steatohepatitis (NASH).1 NAFLD is associated with metabolic disorders, including obesity, hypertension, dyslipidaemia, type 2 diabetes mellitus (T2DM), hypothyroidism and metabolic syndrome.2 The diagnosis of NAFLD requires ≥5% histologic or imaging evidence of hepatic steatosis, with exclusion of secondary causes of hepatic steatosis, such as significant alcohol consumption, hereditary disorders and […]